Codexis [CDXS] vs Bright Minds [DRUG] Detailed Stock Comparison
Codexis
NASDAQ
Loading...
Bright Minds
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Codexis wins in 5 metrics, Bright Minds wins in 10 metrics, with 0 ties. Bright Minds appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Codexis | Bright Minds | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.82 | 0.28 | Codexis |
| Price-to-Book Ratio | 4.43 | 5.44 | Codexis |
| Debt-to-Equity Ratio | 124.00 | 0.27 | Bright Minds |
| PEG Ratio | 0.06 | 0.00 | Bright Minds |
| EV/EBITDA | -4.76 | -81.84 | Bright Minds |
| Profit Margin (TTM) | -113.67% | 0.00% | Bright Minds |
| Operating Margin (TTM) | -83.91% | 0.00% | Bright Minds |
| Return on Equity | -111.00% | -30.79% | Bright Minds |
| Return on Assets (TTM) | -26.48% | -18.31% | Bright Minds |
| Free Cash Flow (TTM) | $-53.72M | $-1.34M | Bright Minds |
| 1-Year Return | -11.68% | 3,562.50% | Bright Minds |
| Price-to-Sales Ratio (TTM) | 4.31 | N/A | N/A |
| Enterprise Value | $249.08M | $162.59M | Codexis |
| EV/Revenue Ratio | 4.36 | N/A | N/A |
| Gross Profit Margin (TTM) | 86.31% | N/A | N/A |
| Revenue per Share (TTM) | $1 | $0 | Codexis |
| Earnings per Share (Diluted) | $-0.80 | $-1.00 | Codexis |
| Beta (Stock Volatility) | 2.55 | 0.17 | Bright Minds |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Codexis vs Bright Minds Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Codexis | 0.41% | -11.03% | -14.79% | 3.86% | -9.70% | -51.60% |
| Bright Minds | 1.57% | 3.10% | 23.91% | 59.53% | 36.36% | 6.91% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Codexis | -11.68% | -67.99% | -78.79% | -34.24% | -70.12% | -82.76% |
| Bright Minds | 3,562.50% | 459.87% | 64.30% | 64.30% | 64.30% | 64.30% |
Performance & Financial Health Analysis: Codexis vs Bright Minds
| Metric | CDXS | DRUG |
|---|---|---|
| Market Information | ||
| Market Cap | $226.56M | $245.98M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 1,360,200 | 33,611 |
| 90 Day Avg. Volume | 1,167,960 | 49,440 |
| Last Close | $2.42 | $43.95 |
| 52 Week Range | $1.90 - $6.08 | $0.94 - $79.02 |
| % from 52W High | -60.20% | -44.38% |
| All-Time High | $42.01 (Nov 08, 2021) | $79.02 (Oct 14, 2024) |
| % from All-Time High | -94.24% | -44.38% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.92% | N/A |
| Quarterly Earnings Growth | 0.92% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -1.14% | 0.00% |
| Operating Margin (TTM) | -0.84% | 0.00% |
| Return on Equity (TTM) | -1.11% | -0.31% |
| Debt to Equity (MRQ) | 124.00 | 0.27 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.62 | $7.32 |
| Cash per Share (MRQ) | $0.74 | $7.25 |
| Operating Cash Flow (TTM) | $-61,218,000 | $-5,718,539 |
| Levered Free Cash Flow (TTM) | $-45,006,500 | $-2,511,345 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Codexis vs Bright Minds
| Metric | CDXS | DRUG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.82 | 0.28 |
| Forward P/E | -3.96 | -6.21 |
| PEG Ratio | 0.06 | 0.00 |
| Price to Sales (TTM) | 4.31 | N/A |
| Price to Book (MRQ) | 4.43 | 5.44 |
| Market Capitalization | ||
| Market Capitalization | $226.56M | $245.98M |
| Enterprise Value | $249.08M | $162.59M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.36 | N/A |
| Enterprise to EBITDA | -4.76 | -81.84 |
| Risk & Other Metrics | ||
| Beta | 2.55 | 0.17 |
| Book Value per Share (MRQ) | $0.62 | $7.32 |
Financial Statements Comparison: Codexis vs Bright Minds
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CDXS | DRUG |
|---|---|---|
| Revenue/Sales | $15.33M | $0 |
| Cost of Goods Sold | $2.10M | N/A |
| Gross Profit | $13.23M | N/A |
| Research & Development | $13.78M | $1.95M |
| Operating Income (EBIT) | $-12.86M | $-2.39M |
| EBITDA | $-10.21M | $-434,820 |
| Pre-Tax Income | $-13.26M | $-3.80M |
| Income Tax | $10,000 | N/A |
| Net Income (Profit) | $-13.27M | $-3.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CDXS | DRUG |
|---|---|---|
| Cash & Equivalents | $18.32M | $37.26M |
| Total Current Assets | $77.81M | $37.97M |
| Total Current Liabilities | $20.90M | $438,653 |
| Long-Term Debt | $56.58M | $45,564 |
| Total Shareholders Equity | $49.63M | $37.58M |
| Retained Earnings | $-583.49M | $-30.81M |
| Property, Plant & Equipment | $64.18M | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CDXS | DRUG |
|---|---|---|
| Operating Cash Flow | $-13.39M | $-4.08M |
| Capital Expenditures | $-1.26M | N/A |
| Free Cash Flow | $-15.05M | $-2.54M |
| Debt Repayment | N/A | $-18,576 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CDXS | DRUG |
|---|---|---|
| Shares Short | 5.19M | 201,534 |
| Short Ratio | 5.15 | 3.99 |
| Short % of Float | 0.06% | 0.04% |
| Average Daily Volume (10 Day) | 1,360,200 | 33,611 |
| Average Daily Volume (90 Day) | 1,167,960 | 49,440 |
| Shares Outstanding | 81.85M | 3.28M |
| Float Shares | 68.49M | 3.00M |
| % Held by Insiders | 0.02% | 0.22% |
| % Held by Institutions | 0.81% | 0.74% |
Dividend Analysis & Yield Comparison: Codexis vs Bright Minds
| Metric | CDXS | DRUG |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |